Search results for "antidiabetic drugs"

showing 4 items of 4 documents

RESUMEN EJECUTIVO DEL CONSENSO DE EXPERTOS SOBRE LA EFICACIA Y SEGURIDAD DE LOS iDPP-4 EN EL TRATAMIENTO DE PACIENTES CON DIABETES Y COVID-19

2021

Resumen Antecedentes El objetivo de este consenso es esclarecer el papel de los iDPP-4 en el manejo de los pacientes con diabetes durante la pandemia por COVID-19. Material y metodos Se llevo a cabo una busqueda bibliografica en PubMed (diciembre 2019-febrero de 2021). Se empleo la metodologia Oxford y se establecieron de forma consensuada posibles recomendaciones. Resultados La diabetes parece ser un factor independiente en la enfermedad de COVID-19 (evidencia 2b). No se demuestra mayor riesgo de contagio con iDPP-4 (evidencia 2b), y su uso ha demostrado ser seguro (evidencia 2b). Los iDPP-4 pueden presentar un cierto beneficio en la reduccion de la mortalidad, particularmente su uso intra…

Nutrition and DieteticsdiabetesEndocrinology Diabetes and MetabolismAntidiabetic drugsDiabetesCOVID-19antidiabetic drugsiDPP-4mortalityArticleEndocrinologymortalidadMortalityfármacos antidiabéticosEndocrinologia, Diabetes Y Nutricion
researchProduct

Manejo de la hiperglucemia con fármacos no insulínicos en pacientes adultos con diabetes tipo 2

2019

Resumen: El adecuado tratamiento de la diabetes mellitus tipo 2 (DM2) incluye la alimentación saludable y el ejercicio (150 min/semana) como pilares básicos. Para el tratamiento farmacológico, la metformina es el fármaco de elección inicial, salvo contraindicación o intolerancia; en caso de mal control, se dispone de 8 familias terapéuticas (6 orales y 2 inyectables) como posibles combinaciones. Se presenta un algoritmo y unas recomendaciones para el tratamiento de la DM2. En prevención secundaria cardiovascular se recomienda asociar un inhibidor del cotransportador sodio-glucosa tipo 2 (iSGLT2) o un agonista del receptor de glucagon-like peptide-1 (arGLP1) en pacientes con obesidad. En pre…

Agonistmedicine.medical_specialtymedicine.drug_class030204 cardiovascular system & hematologyOverweight:Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena::Diet::Diabetic Diet [Medical Subject Headings]GastroenterologyDiabetes tipo 2:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]03 medical and health sciences0302 clinical medicineFármacos antidiabéticos:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperglycemia [Medical Subject Headings]Internal medicineDiabetes mellitusmedicineGliclazide030212 general & internal medicineHiperglucemiaContraindicationlcsh:R5-920business.industryAntidiabetic drugs:Diseases::Endocrine System Diseases::Diabetes Mellitus::Diabetes Mellitus Type 2 [Medical Subject Headings]nutritional and metabolic diseases:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Psychology Social::Life Style [Medical Subject Headings]Type 2 diabetesGeneral Medicinemedicine.diseaseSulfonylureaObesityHumanos:Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity [Medical Subject Headings]MetforminHyperglycemia:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hypoglycemic Agents [Medical Subject Headings]medicine.symptomlcsh:Medicine (General)Family Practicebusinessmedicine.drug
researchProduct

Activation of AMPK by medicinal plants and natural products: Its role in type 2 diabetes mellitus

2019

Type-2 Diabetes (T2D) is a metabolic disease characterized by permanent hyperglycemia, whose development can be prevented or delayed by using therapeutic agents and implementing lifestyle changes. Some therapeutic alternatives include regulation of glycemia through modulation of different mediators and enzymes, such as AMP-activated protein kinase (AMPK), a highly relevant cellular energy sensor for metabolic homeostasis regulation, with particular relevance in the modulation of liver and muscle insulin sensitivity. This makes it a potential therapeutic target for antidiabetic drugs. In fact, some of them are standard drugs used for treatment of T2D, such as biguanides and thiazoli-dindione…

AMPKCIENCIAS MÉDICAS Y DE LA SALUDBiguanidesAMP-Activated Protein KinasesPharmacologyResveratrolCarbohydrate metabolismNATURAL PRODUCTS03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBerberineDiabetes mellitusDrug DiscoveryHumansHypoglycemic AgentsMedicineTYPE 2 DIABETES MELLITUSProtein kinase A030304 developmental biologyPharmacologychemistry.chemical_classificationBiological Products0303 health sciencesPlants Medicinalbusiness.industryType 2 Diabetes MellitusAMPKGeneral MedicineBioquímica y Biología Molecularmedicine.diseaseANTIDIABETIC DRUGSMedicina BásicaGlucoseEnzymeDiabetes Mellitus Type 2chemistry030220 oncology & carcinogenesisThiazolidinedionesbusinessMEDICINAL PLANTS
researchProduct

An Exploratory Research of 18 Years on the Economic Burden of Diabetes for the Romanian National Health Insurance System

2020

The prevalence of diabetes mellitus (DM) rises constantly each year worldwide. Because of that, the funds allocated for the DM treatment have increased over time. Regarding the number of DM cases, Romania is among the top ten countries in Europe. Based on the National Diabetes Programme (NDP), antidiabetic drugs and other expenditures (Self-monitoring blood glucose (SMBG) test, HbA1c, insulin pumps/insulin pumps supplies) are free of charge. This programme has undergone many changes in drugs supply, in the last two decades: re-organizing the NDP, authorization of new molecules with high prices (e.g., SGLT-2 inhibitors, etc.) or new devices (e.g., insulin pumps, etc.) The main purpose of thi…

National Health Programsefficiency indicatorsHealth Toxicology and Mutagenesismedicine.medical_treatmentExploratory researchlcsh:Medicinediabetes mellitus costantidiabetic drugs030209 endocrinology & metabolismArticleNational Diabetes Programme03 medical and health sciencesPharmacoeconomics0302 clinical medicineCost of IllnesspharmacoeconomicsInflation rateDiabetes mellitusHumansMedicine030212 general & internal medicinephysical indicatorsRetrospective StudiesRomaniabusiness.industryOptimal treatmentInsulinlcsh:RPublic Health Environmental and Occupational Healthmedicine.diseaseEuropeDiabetes Mellitus Type 2National health insuranceRomanian National Health Insurance SystemDiabetic patientbusinessDemographyInternational Journal of Environmental Research and Public Health
researchProduct